The estimated Net Worth of Nicole Barna is at least $1.52 Thousand dollars as of 29 March 2023. Ms Barna owns over 7,305 units of Codiak BioSciences stock worth over $276 and over the last 4 years she sold CDAK stock worth over $1,242.
Ms has made over 4 trades of the Codiak BioSciences stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 7,305 units of CDAK stock worth $1,242 on 29 March 2023.
The largest trade she's ever made was selling 7,305 units of Codiak BioSciences stock on 29 March 2023 worth over $1,242. On average, Ms trades about 2,506 units every 48 days since 2021. As of 29 March 2023 she still owns at least 4,849 units of Codiak BioSciences stock.
You can see the complete history of Ms Barna stock trades at the bottom of the page.
Nicole Barna is the Sr. VP of HR at Codiak BioSciences.
Ms Barna is 47, she's been the Sr. VP of HR of Codiak BioSciences since . There are 7 older and no younger executives at Codiak BioSciences. The oldest executive at Codiak BioSciences, Inc. is Richard Brudnick, 64, who is the Chief Bus. Officer & Head of Corp. Strategy.
Nicole's mailing address filed with the SEC is C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE, MA, 02140.
Over the last 4 years, insiders at Codiak BioSciences have traded over $15,220 worth of Codiak BioSciences stock and bought 11,821,475 units worth $20,798,957 . The most active insiders traders include Steven Gillis, Venture Fund Viii, L.P.Arch..., and Permanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of $19,158. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth $326.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Codiak BioSciences executives and other stock owners filed with the SEC include: